×

Lyophilized formulations of exendins and exendin agonist analogs

  • US 7,906,146 B2
  • Filed: 02/20/2009
  • Issued: 03/15/2011
  • Est. Priority Date: 01/14/1999
  • Status: Expired due to Fees
First Claim
Patent Images

1. A lyophilized formulation comprising about 0.005% (w/v) to about 0.4% (w/v) exendin-4 and about 1.0% (w/v) to about 10% (w/v) mannitol.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×